Cladribine in the treatment of acute myeloid leukemia

a single-institution experience.

Michael Martin, John S. Welch, Kristan Augustin, Lindsay Hladnik, John F. DiPersio, Camille N. Abboud

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND: Despite advances in novel therapeutics, supportive care, and postremission therapy, the outcome of high-risk and elderly patients as well as those with relapsed/refractory acute myeloid leukemia (AML) remains poor. There is likely still room for improvement through optimizing conventional chemotherapy. PATIENTS AND METHODS: Through a pharmacy database search we identified all patients with AML treated at Washington University with cladribine-based regimens. RESULTS: Twenty-four patients were identified that were treated with 2 cladribine-based regimens: CLAG (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5] and granulocyte colony-stimulating factor [G-CSF; 300 microg subcutaneously (s.c.) days 0-5]) and CLAM (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5], G-CSF [300 mg s.c. days 0-5] and mitoxantrone [10 mg/m2 days 1-3]). Complete responses were achieved in 53% of patients given induction chemotherapy and 44% of those given salvage chemotherapy. The regimens were well tolerated with minimal extramedullary toxicity. CONCLUSION: These data suggest that cladrabine-based regimens should be further explored in both the salvage and first-line setting and might offer an attractive backbone on which to add novel therapies.

Original languageEnglish (US)
Pages (from-to)298-301
Number of pages4
JournalClinical lymphoma & myeloma
Volume9
Issue number4
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Cladribine
Acute Myeloid Leukemia
Granulocyte Colony-Stimulating Factor
Cytarabine
Drug Therapy
Mitoxantrone
Induction Chemotherapy
Therapeutics
Databases

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Cladribine in the treatment of acute myeloid leukemia : a single-institution experience. / Martin, Michael; Welch, John S.; Augustin, Kristan; Hladnik, Lindsay; DiPersio, John F.; Abboud, Camille N.

In: Clinical lymphoma & myeloma, Vol. 9, No. 4, 01.01.2009, p. 298-301.

Research output: Contribution to journalArticle

Martin, Michael ; Welch, John S. ; Augustin, Kristan ; Hladnik, Lindsay ; DiPersio, John F. ; Abboud, Camille N. / Cladribine in the treatment of acute myeloid leukemia : a single-institution experience. In: Clinical lymphoma & myeloma. 2009 ; Vol. 9, No. 4. pp. 298-301.
@article{1c615b248e4c4db984f22623e9ae50c2,
title = "Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.",
abstract = "BACKGROUND: Despite advances in novel therapeutics, supportive care, and postremission therapy, the outcome of high-risk and elderly patients as well as those with relapsed/refractory acute myeloid leukemia (AML) remains poor. There is likely still room for improvement through optimizing conventional chemotherapy. PATIENTS AND METHODS: Through a pharmacy database search we identified all patients with AML treated at Washington University with cladribine-based regimens. RESULTS: Twenty-four patients were identified that were treated with 2 cladribine-based regimens: CLAG (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5] and granulocyte colony-stimulating factor [G-CSF; 300 microg subcutaneously (s.c.) days 0-5]) and CLAM (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5], G-CSF [300 mg s.c. days 0-5] and mitoxantrone [10 mg/m2 days 1-3]). Complete responses were achieved in 53{\%} of patients given induction chemotherapy and 44{\%} of those given salvage chemotherapy. The regimens were well tolerated with minimal extramedullary toxicity. CONCLUSION: These data suggest that cladrabine-based regimens should be further explored in both the salvage and first-line setting and might offer an attractive backbone on which to add novel therapies.",
author = "Michael Martin and Welch, {John S.} and Kristan Augustin and Lindsay Hladnik and DiPersio, {John F.} and Abboud, {Camille N.}",
year = "2009",
month = "1",
day = "1",
doi = "10.3816/CLM.2009.n.058",
language = "English (US)",
volume = "9",
pages = "298--301",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "4",

}

TY - JOUR

T1 - Cladribine in the treatment of acute myeloid leukemia

T2 - a single-institution experience.

AU - Martin, Michael

AU - Welch, John S.

AU - Augustin, Kristan

AU - Hladnik, Lindsay

AU - DiPersio, John F.

AU - Abboud, Camille N.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - BACKGROUND: Despite advances in novel therapeutics, supportive care, and postremission therapy, the outcome of high-risk and elderly patients as well as those with relapsed/refractory acute myeloid leukemia (AML) remains poor. There is likely still room for improvement through optimizing conventional chemotherapy. PATIENTS AND METHODS: Through a pharmacy database search we identified all patients with AML treated at Washington University with cladribine-based regimens. RESULTS: Twenty-four patients were identified that were treated with 2 cladribine-based regimens: CLAG (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5] and granulocyte colony-stimulating factor [G-CSF; 300 microg subcutaneously (s.c.) days 0-5]) and CLAM (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5], G-CSF [300 mg s.c. days 0-5] and mitoxantrone [10 mg/m2 days 1-3]). Complete responses were achieved in 53% of patients given induction chemotherapy and 44% of those given salvage chemotherapy. The regimens were well tolerated with minimal extramedullary toxicity. CONCLUSION: These data suggest that cladrabine-based regimens should be further explored in both the salvage and first-line setting and might offer an attractive backbone on which to add novel therapies.

AB - BACKGROUND: Despite advances in novel therapeutics, supportive care, and postremission therapy, the outcome of high-risk and elderly patients as well as those with relapsed/refractory acute myeloid leukemia (AML) remains poor. There is likely still room for improvement through optimizing conventional chemotherapy. PATIENTS AND METHODS: Through a pharmacy database search we identified all patients with AML treated at Washington University with cladribine-based regimens. RESULTS: Twenty-four patients were identified that were treated with 2 cladribine-based regimens: CLAG (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5] and granulocyte colony-stimulating factor [G-CSF; 300 microg subcutaneously (s.c.) days 0-5]) and CLAM (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5], G-CSF [300 mg s.c. days 0-5] and mitoxantrone [10 mg/m2 days 1-3]). Complete responses were achieved in 53% of patients given induction chemotherapy and 44% of those given salvage chemotherapy. The regimens were well tolerated with minimal extramedullary toxicity. CONCLUSION: These data suggest that cladrabine-based regimens should be further explored in both the salvage and first-line setting and might offer an attractive backbone on which to add novel therapies.

UR - http://www.scopus.com/inward/record.url?scp=77449098778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449098778&partnerID=8YFLogxK

U2 - 10.3816/CLM.2009.n.058

DO - 10.3816/CLM.2009.n.058

M3 - Article

VL - 9

SP - 298

EP - 301

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 4

ER -